Leica launches Autiva Spatial Phenotyper, combining automated cyclic staining, high-plex imaging and AI analysis

Leica Microsystems announced the launch of Autiva Spatial Phenotyper on 28 September 2026. The platform combines automated cyclic staining/de-staining, multiplex imaging, an ATTOAuriga reagent ecosystem and Aivia AI-powered analysis within one spatial-biology workflow.

CFCM explainer — the spatial phenotyping chain

Cyclic staining/de-staining → multiplex imaging → AI segmentation and phenotype classification → spatial cell–cell relationships.

Source/credit: CFCM workflow explainer based on the Leica Microsystems launch release, checked 3 October 2026. Alt text: workflow showing cyclic staining, multiplex imaging, AI phenotyping and spatial context.

Leica states that Autiva can process up to four slides in parallel and complete 24-plex experiments overnight. The company also promotes up to threefold higher throughput; CFCM records that figure as a manufacturer claim rather than independently established performance.

Autiva is a spatial-imaging platform, not a flow cytometer. The “up to 3× higher throughput” statement is manufacturer-generated. The launch does not establish equivalence with flow cytometry, clinical diagnostic performance or IVD authorization.

High-dimensional phenotyping is no longer owned by one measurement architecture. Flow provides very large event counts but loses tissue architecture; spatial imaging preserves location and cell–cell relationships with different throughput, sampling and validation constraints. CFCM should track that adjacent market without presenting it as a replacement for clinical flow.